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Fatty	liver	is	commonly	associated	with	alcohol	ingestion	and	abuse.	While	the	molecular	pathogenesis	of	
these	fatty	changes	is	well	understood,	the	biochemical	and	pharmacological	mechanisms	by	which	ethanol	
stimulates	these	molecular	changes	remain	unknown.	During	ethanol	metabolism,	adenosine	is	generated	by	
the	enzyme	ecto-5′-nucleotidase,	and	adenosine	production	and	adenosine	receptor	activation	are	known	to	
play	critical	roles	in	the	development	of	hepatic	fibrosis.	We	therefore	investigated	whether	adenosine	and	
its	receptors	play	a	role	in	the	development	of	alcohol-induced	fatty	liver.	WT	mice	fed	ethanol	on	the	Lieber-
DeCarli	diet	developed	hepatic	steatosis,	including	increased	hepatic	triglyceride	content,	while	mice	lacking	
ecto-5′-nucleotidase	or	adenosine	A1	or	A2B	receptors	were	protected	from	developing	fatty	liver.	Similar	pro-
tection	was	also	seen	in	WT	mice	treated	with	either	an	adenosine	A1	or	A2B	receptor	antagonist.	Steatotic	livers	
demonstrated	increased	expression	of	genes	involved	in	fatty	acid	synthesis,	which	was	prevented	by	blockade	
of	adenosine	A1	receptors,	and	decreased	expression	of	genes	involved	in	fatty	acid	metabolism,	which	was	
prevented	by	blockade	of	adenosine	A2B	receptors.	In	vitro	studies	supported	roles	for	adenosine	A1	recep-
tors	in	promoting	fatty	acid	synthesis	and	for	A2B	receptors	in	decreasing	fatty	acid	metabolism.	These	results	
indicate	that	adenosine	generated	by	ethanol	metabolism	plays	an	important	role	in	ethanol-induced	hepatic	
steatosis	via	both	A1	and	A2B	receptors	and	suggest	that	targeting	adenosine	receptors	may	be	effective	in	the	
prevention	of	alcohol-induced	fatty	liver.
Introduction
Fatty liver is the most common and earliest response of the 
liver to heavy alcohol consumption and may develop into alco-
holic hepatitis and fibrosis. Although fatty liver is a very com-
mon medical problem and the molecular events involved in the 
pathogenesis of fatty liver are well understood, the connection 
between ethanol ingestion and metabolism and the activation 
of the events involved in the development of hepatic steatosis is 
not well understood.
Ethanol is sequentially metabolized to acetaldehyde and acetate by 
the actions of alcohol dehydrogenase and aldehyde dehydrogenase, 
respectively. Acetate is further metabolized to acetyl-CoA accompa-
nied by the catabolism of ATP to AMP. Ethanol is well known to 
stimulate increased extracellular adenosine concentration in vitro 
through its action on the nucleoside transporter, and ethanol inges-
tion increases purine release into the bloodstream and urine in nor-
mal volunteers (1–3) and into the extracellular space in liver slices 
from ethanol-treated mice and those from cultured hepatocyte cell 
line (HepG2) (4, 5). Adenosine is present in and released from nearly 
all mammalian tissues and organs, and increased adenosine con-
centrations result from either increased export of adenosine, dimin-
ished uptake of adenosine, or cellular release of adenine nucleotides, 
which are dephosphorylated extracellularly to adenosine (6). Increas-
ing evidence indicates that most extracellular adenosine is derived 
from adenine nucleotides released from cells, extracellular ATP and 
ADP are dephosphorylated to AMP by the action of nucleoside tri-
phosphate phosphohydrolase (CD39) or other phosphatases, and 
AMP is further dephosphorylated to adenosine by ecto-5′-nucleotid-
ase (CD73) or alkaline phosphatase (7, 8). Extracellular adenosine 
regulates a variety of physical processes (9) and adenosine’s effects 
are mediated by a family of 4 G protein–coupled receptors, A1, A2A, 
A2B, and A3, each of which has a unique pharmacological profile, 
tissue distribution, and effector coupling (10).
Because prior studies have demonstrated a role for adenosine 
and its receptors in the regulation of hepatic fibrosis (4, 5), hepatic 
ureagenesis (11, 12), and glycogen metabolism (13, 14) as well as 
peripheral lipid metabolism (15, 16), we determined whether ade-
nosine and its receptors play a role in the pathogenesis of hepatic 
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steatosis induced by ethanol ingestion. Here, we report evidence 
that ethanol-mediated increases in extracellular adenosine, acting 
via adenosine A1 and A2B receptors, link the ingestion and metabo-
lism of ethanol to the development of hepatic steatosis.
Results
Deletion of ecto-5′-nucleotidase prevents the development of ethanol-induced 
fatty liver in mice. We have previously demonstrated that livers from 
mice that have been exposed to ethanol release more adenosine 
ex vivo than livers of mice that were not exposed to ethanol, and 
the increased adenosine release depends on extracellular dephos-
phorylation of AMP to adenosine by CD73 (5). We therefore 
determined whether CD73-dependent adenosine accumulation 
plays a role in development of ethanol-induced hepatic steatosis. 
WT mice developed severe hepatic steatosis after chronic ethanol 
ingestion but CD73-knockout mice (CD73KO mice) suffered only 
minimal fatty change (Figure 1, A and C). Consistent with the his-
tological appearance, the hepatic triglycerides levels were much 
lower in ethanol-fed CD73KO mice than in WT mice (Figure 1G). 
Serum aspartate aminotransferase (AST) and triglyceride levels 
were significantly lower in CD73KO mice than in WT mice as well 
(Table 1 and Figure 1, E and F).
Deletion of adenosine A1 or A2B receptors protects mice from developing 
ethanol-induced fatty liver. Adenosine and its receptors play a role in 
Figure 1
Deletion of ecto-5′-nucleotidase prevents 
the development of ethanol-induced fatty 
liver in mice. Eight-week-old male mice (WT 
and CD73KO mice) were fed a liquid diet 
containing ethanol or an equal caloric diet 
containing maltose for 6 weeks. Mice were 
then sacrificed at the end of sixth week, and 
their livers were collected and stained with 
H&E and Oil Red O. The livers and bod-
ies of the mice were weighed on the day of 
sacrifice and the liver/total body weight ratio 
was calculated. The serum AST and triglyc-
eride and hepatic tissue triglyceride levels 
were also measured, as described in Meth-
ods. The hepatic steatosis grade was based 
on the percentage of steatotic hepatocytes 
in the H&E-stained liver sections. (A) H&E-
stained liver sections from maltose- and 
ethanol-treated WT and CD73KO mice 
(original magnification, ×400). (B) Hepatic 
steatosis grades of ethanol-treated WT and 
CD73KO mice. Steatosis grades in malt-
ose-treated WT and CD73KO mice were 0. 
(C) Oil Red O–stained liver sections from 
WT and ethanol-treated WT and CD73KO 
mice (original magnification, ×400). (D) 
Liver/body weight ratio of CD73KO and 
WT mice. (E) Serum AST levels of WT and 
CD73KO mice. (F) Serum triglyceride levels 
of WT and CD73KO mice. (G) Hepatic tis-
sue triglyceride levels in WT and CD73KO 
mice. #P < 0.01, CD73KO mice versus WT 
mice; *P < 0.01, ethanol mice versus con-
trol mice in different groups, respectively; 
**P < 0.01, ethanol CD73KO mice versus 
control WT mice or ethanol WT mice, respec-
tively; n = 5–10 for each group of mice.
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the pharmacologic effects of ethanol (reviewed in refs. 17–19), so 
we studied ethanol-induced hepatic steatosis in mice lacking ade-
nosine A1, A2A, and A2B receptors. As shown in Figure 2A, adenosine 
A1 and A2B but not A2A receptor deletion prevents ethanol-induced 
hepatic steatosis (Figure 2, A and B). Interestingly, the liver/total 
body weight ratio did not differ among ethanol-treated WT mice 
and adenosine A1 receptor knockout mice (A1KO mice) or A2BKO 
mice (Figure 2D). Hepatic triglyceride content and steatosis grade 
was lower in the A1KO and A2BKO but not A2AKO mice (Figure 2, 
C and G), and serum triglyceride and AST levels were significantly 
lower in the A1KO and A2BKO but not the A2AKO mice as well 
(Table 1 and Figure 2, E and F).
Blockade of adenosine A1 or A2B receptors protects mice from developing 
ethanol-induced fatty liver. Serum triglyceride and AST levels were ele-
vated in the ethanol-treated WT mice, and AST and triglyceride lev-
els were significantly lower in both enprofylline-treated (A2B recep-
tor antagonist) and 1,3 dipropyl-8-cyclopentylxanthine–treated 
(DPCPX-treated) (A1 receptor antagonist) mice, although there was 
a greater decrease in serum triglyceride levels in the enprofylline-
treated mice (Table 1 and Figure 3, D and E). Similar to the knock-
out mice, there were significant reductions in hepatic triglyceride 
levels in the antagonist-treated mice compared with the vehicle-
treated mice, although the levels did not return to those of mice 
not exposed to ethanol (Figure 3F). As with the hepatic triglycer-
ide level, the hepatic steatosis grade was significantly decreased in 
all of the antagonist-treated mice compared with vehicle-treated 
mice (Figure 3B). Interestingly, the reduction in steatosis grade was 
greater in the receptor knockout and antagonist-treated mice than 
in CD73KO mice (Figure 1B and Figure 3B).
Ethanol ingestion increases hepatic expression of mRNA for ecto-5′-nucle-
otidase and adenosine A1, A2A, and A2B receptors. Hepatic adenosine 
receptor mRNA expression increases after chronic CCL4 treatment 
(4, 5). We therefore asked whether chronic ethanol treatment also 
regulates expression of CD73 and adenosine receptors. Chronic 
ethanol ingestion leads to a significant increase in CD73 and ade-
nosine A1, A2B, and A2A receptor mRNA (A1R, A2bR, A2aR) expres-
sion as compared with corresponding control mice, 
respectively (Figure 4A). Interestingly, the increase in 
mRNA for CD73, A1R, and A2bR was greater than that 
for A2aR (Figure 4A).
Ethanol ingestion modulates expression of hepatic 
transcription factors SREBP1 and PPARα and hepatic 
enzymes and transporters involved in fatty acid synthe-
sis, metabolism, and transport. Increased or decreased 
expression/function of specific transcriptional regu-
lators plays a role in the development of hepatic ste-
atosis: SREBP1 increases expression of genes/proteins 
involved in lipid synthesis (including ATP citrate lyase 
[ACL] and fatty acid synthase [FAS]) (20–22), PPARα 
regulates proteins involved in fatty acid oxidation 
(e.g., acetyl-CoA carboxylase [ACC] and carnitine pal-
mitoyltransferase [CPT]) (23–25), and PPARγ mainly 
regulates lipogenesis (26–29). We therefore measured 
expression of mRNA for Srebp1, Ppara, Pparg, Acl, Fas, 
Acca, and Cpt1. Chronic ethanol ingestion increased 
mRNA expression of Srebp1, Pparg, Acl, and Fas in livers 
from WT, A2BKO, and enprofylline-treated mice, but 
adenosine A1 receptor deletion or blockade (DPCPX 
treatment) prevented the ethanol-induced increase 
in expression (Figure 4, B, D–F). In contrast, ethanol 
ingestion reduced mRNA expression of Ppara, Cpt1, and Acca in 
the livers of WT, A1KO, and DPCPX-treated mice, but deletion or 
blockade of A2B receptors abrogated the ethanol-induced reduction 
in expression (Figure 4, C, G, and H).
A1 and A2B adenosine receptor agonists promote lipid accumulation 
in a cultured murine hepatocyte cell line. To better understand how 
adenosine A1 and A2B receptors are involved in the formation of 
fatty liver in vivo, we examined the effect of selective A1 and A2B 
receptor agonists and antagonists on development of steatosis in 
an hepatocyte cell line (AML-12). AML-12 cells express mRNA for 
all 4 adenosine receptors (data not shown). Following treatment 
with the A1 receptor agonist N6-cyclopentyladenosine (CPA) or the 
nonselective adenosine receptor agonist 5′-N-ethylcarboxamido-
adenosine (NECA) at a concentration that activates A2B receptors, 
AML-12 cells accumulated lipid, as demonstrated by Oil Red O 
staining, and increased their intracellular triglyceride levels in a 
dose-dependent fashion (Figure 5, A–C). Addition of the adenos-
ine A1 or A2B selective antagonists DPCPX or N-(4-aceptylphenyl)-
2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purine-8-yl) 
phenoxy]acetamide (MRS1706), respectively, abrogated the effects 
of the A1 and A2B receptor agonists on hepatocyte triglyceride 
accumulation, but neither A2A nor A3 adenosine receptor blockade 
reversed the effects of either CPA or NECA on triglyceride accumu-
lation (Figure 5, A, D, and E).
Adenosine A1 and A2B receptors regulate nuclear SREBP1, 
PPARα, and PPARγ protein levels and transcriptional activity in 
AML-12 cells. We studied the effects of adenosine A1 and A2B recep-
tor agonists and antagonists on nuclear SREBP1, PPARα, and 
PPARγ protein levels and the transcriptional activities of PPARα 
and PPARγ in AML-12 cells. Nuclear SREBP1 and PPARγ but not 
PPARα protein levels were significantly increased after CPA treat-
ment, effects that were completely blocked by DPCPX (Figure 6, 
A, B, and D). In contrast, nuclear PPARα protein levels were mark-
edly diminished following NECA treatment, and the selective A2B 
receptor antagonist MRS1706 abrogated this decrease (Figure 6, 
A and C). A1 receptor activation increased PPARγ but not PPARα 
Table 1
Mouse body weight changes and serum ALT and AST levels
Mice	 Group	 BW	(%,	versus		 ALT	(IU/l)	 AST	(IU/l)
	 	 before	treatment)
WT Control 33.1 ± 3.9 197.4 ± 23.5 175.5 ± 21.3
 Ethanol 20.4 ± 2.8A 137.0 ± 9.1A 230.6 ± 26.4A
CD73 Control 28.2 ± 1.8 187.7 ± 9.6 165.3 ± 11.7
 Ethanol 26.6 ± 2.4 181.4 ± 19.7 165.9 ± 17.1
A1KO Control 34.6 ± 5.9 184.0 ± 17.3 171.7 ± 15.4
 Ethanol 31.7 ± 3.1 137.5 ± 13.3A 162.7 ± 21.8
A2BKO Control 39.5 ± 2.9 181.0 ± 18.4 169.0 ± 7.1
 Ethanol 35.7 ± 4.4 183.7 ± 27.4 166.5 ± 13.6
WT Ethanol + DPCPX 32.1 ± 4.9B 158.8 ± 11.5C 166.2 ± 17.4B
WT Ethanol + enpro 34.0 ± 5.4B 154.1 ± 15.2C 161.6 ± 11.3B
A2AWT Control 33.8 ± 1.0 168.3 ± 12.4 148.0 ± 7.0
 Ethanol 17.5 ± 1.8A 184.7 ± 16.4 173.3 ± 13.7A
A2AKO Control 30.1 ± 2.8 169.5 ± 15.4 147.0 ± 9.0
 Ethanol 17.7 ± 2.5A 197.7 ± 18.5 183.4 ± 16.8A
Mice were fed an isocaloric liquid Lieber-DeCarli diet containing either ethanol or malt-
ose, as described in Methods. ALT, alanine aminotransferase; enpro, enprofylline.  
AP < 0.01, ethanol versus control; BP < 0.01, DPCPX or enprofylline versus WT etha-
nol; CP < 0.01, DPCPX or enprofylline versus WT control or WT ethanol, respectively.
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Figure 2
Deletion of adenosine A1 or A2B receptors protects mice from developing ethanol-induced fatty liver. Eight-week-old male mice (WT, A1KO, 
A2BKO, A2AWT, and A2AKO mice) were fed a liquid diet containing ethanol or an equal caloric diet containing maltose for 6 weeks and then 
sacrificed. The livers and bodies of the mice were weighed on the day of sacrifice and the liver/total body weight ratio was calculated. The serum 
AST and triglyceride and hepatic tissue triglyceride levels were also measured, as described in Methods. The hepatic steatosis grade was based 
on the percentage of steatotic hepatocytes in the H&E-stained liver sections. (A) H&E-stained liver sections from maltose- and ethanol-treated 
A1KO, A2BKO, A2AWT, and A2AKO mice (original magnification, ×400). (B) Oil Red O–stained liver sections from ethanol-treated A1KO and 
A2BKO mice (original magnification, ×400). (C) Hepatic steatosis grades of ethanol-treated WT, A1KO, A2BKO, A2AWT, and A2AKO mice. 
Steatosis grades in maltose-treated WT, A1KO, A2BKO, A2AWT, and A2AKO mice were 0. (D) Liver/body weight ratio. (E) Serum AST lev-
els. (F) Serum triglyceride levels. (G) Hepatic tissue triglyceride levels. #P < 0.01, A1KO mice or A2BKO mice versus WT mice, respectively; 
*P < 0.01, ethanol mice versus control mice in different groups, respectively; **P < 0.01, ethanol KO mice versus control KO mice or control WT 
mice or ethanol WT mice, respectively; n = 5–10 for each group of mice.
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transcriptional activity, whereas A2B receptor activation increased 
PPARα but not PPARγ transcriptional activity (Figure 6, E and F). 
These results are consistent with the hypothesis that adenosine A1 
and A2B receptors regulate hepatic fat metabolism by increasing or 
decreasing appropriate transcriptional regulators.
Adenosine A1 and A2B receptors regulate enzymes involved in fatty 
acid synthesis and oxidation. We next measured cellular content of 
enzymes and proteins involved in 
fatty acid synthesis and oxidation 
downstream of the transcriptional 
regulators that are regulated by 
adenosine receptor occupancy. The 
expression of the fatty acid synthet-
ic enzymes ACL and FAS is regulat-
ed by SREBP1 and PPARγ, whereas 
expression of the fatty acid meta-
bolic enzyme ACCα and the fatty 
acid transporter CPTI is regulated 
by PPARα. Cellular ACL and FAS 
protein levels were significantly 
increased after A1 receptor activa-
tion, without any effect on ACCα 
or CPTI protein levels, while the 
A1 antagonist DPCPX completely 
reversed this increase (Figure 7). 
In contrast, A2B receptor activa-
tion diminished ACCα and CPTI 
protein levels but did not affect 
ACL or FAS levels, and A2B recep-
tor blockade completely abrogated 
this effect (Figure 7). These results 
are consistent with the effects of 
ethanol and deletion or blockade 
of adenosine A1 or A2B receptors on 
expression of mRNA for these pro-
teins observed in vivo.
Adenosine A2B receptors regulate 
the phosphorylation of a critical 
signaling molecule controlling 
the pathways of hepatic fatty acid 
oxidation. AMP-activated kinase 
(AMPK) is a critical signaling mol-
ecule controlling hepatic fatty acid 
oxidation (30, 31). Therefore, we 
determined whether adenosine 
receptor occupancy regulates the 
phosphorylation and, presumably, 
activation of this critical signaling 
enzyme. Following ethanol treat-
ment, phosphorylated/total AMPK 
ratio was significantly decreased 
in the hepatic tissues of WT mice, 
A1KO mice, and DPCPX-treated 
mice (Figure 8). In contrast, the 
phosphorylated/total AMPK ratio 
was not nearly as diminished in the 
A2BKO and enprofylline-treated 
mice although the ratio did not 
return to the levels observed in 
the mice on a control diet (Figure 
8, A and B). Similarly, when studied in vitro, NECA decreased 
phosphorylated/total AMPK ratio in AML-12 cells, and the spe-
cific adenosine A2B antagonist MRS1706 blocked this effect (Fig-
ure 8, C and D). These results clearly demonstrate that hepatic 
adenosine A2B receptors alter the phosphorylation and, by infer-
ence, the activity of AMPK, a critical signaling intermediate in 
the regulation of fatty acid oxidation.
Figure 3
Blockade of adenosine A1 or A2B receptors protects mice from developing ethanol-induced fatty liver. 
Eight-week-old C57BL/6 male mice were fed a liquid diet containing ethanol or an equal caloric diet 
containing maltose for 6 weeks supplemented with A1 receptor–specific antagonist DPCPX, the A2B 
receptor–specific antagonist enprofylline (enpro), or vehicle and then sacrificed. The livers and bodies 
of the mice were weighed on the day of sacrifice and the liver/total body weight ratio was calculated. 
The serum AST and triglyceride and hepatic tissue triglyceride levels were also measured, as described 
in Methods. The hepatic steatosis grade was based on the percentage of steatotic hepatocytes in the 
H&E-stained liver sections. (A) H&E and Oil Red O staining of liver sections of DPCPX- or enprofylline-
treated mice (original magnification, ×400). (B) Hepatic steatosis grades. (C) Liver/body weight ratio. 
(D) Serum AST levels. (E) Serum triglyceride levels. (F) Hepatic tissue triglyceride levels. #P < 0.01, 
DPCPX- or enprofylline-treated ethanol mice versus ethanol mice in different groups, respectively; 
*P < 0.01, ethanol mice versus DPCPX- or enprofylline-treated ethanol mice in different groups, respec-
tively; **P < 0.01, DPCPX- or enprofylline-treated ethanol mice versus control mice in different groups, 
respectively; ##P < 0.05, DPCPX- or enprofylline-treated ethanol mice versus control mice in different 
groups, respectively; n = 5–10 in each group.
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Adenosine A1, A2A, A2B, and A3 receptors are present in human liver, and 
there are more A2A and A2B receptors in steatotic and cirrhotic livers. Because 
adenosine receptor expression in mice may not reflect expression 
levels in humans, we studied the binding characteristics of human 
adenosine receptor subtypes in healthy or pathologic human liver 
tissue by radioligand binding studies. Adenosine A1, A2A, A2B, and A3 
receptors are present in healthy human liver membranes. In plasma 
membrane preparations from cirrhotic and steatotic livers, there 
were significantly more adenosine A2A and A2B receptors, without 
any change in numbers of A1 or A3 receptors (Table 2).
Discussion
The results reported here demonstrate what we believe to be a 
novel biochemical and pharmacological mechanism for alcohol-
induced fatty liver, a common medical problem. Our results dem-
onstrate that, consistent with results of prior in vitro and in vivo 
studies in animals and humans, ethanol promotes hepatic adenine 
nucleotide release (1, 2), which is subsequently dephosphorylated 
extracellularly to adenosine by the action of CD73 (5). As previ-
ously reported, adenosine levels are further increased as a result 
of diminished adenosine uptake in the liver (32, 33). Chronic 
alcohol-stimulated adenosine release stimulates adenosine A1 and 
A2B receptors, which promote the development of fatty liver, since 
blockade or deletion of these receptors in vivo and blockade of 
these receptors in vitro diminishes hepatic triglyceride accumula-
tion and development of fatty liver.
Adenosine and its receptors regulate a variety of hepatic and 
hepatocellular functions, including glucose release (34, 35), pro-
tein synthesis (36), glutathione synthesis (37), hepatic regulation 
of renal Na+ and water excretion, and portal blood flow (18, 38–40). 
Moreover, ethanol- and acetate-induced adenosine release medi-
ates many of these effects. Thus, although the effects of adenosine 
(whether exogenous or released in response to either ethanol or 
acetate) and its receptors on hepatic triglyceride metabolism have 
Figure 4
Ethanol ingestion increases CD73 and 
A1R, A2aR, and A2bR mRNA expres-
sion, and modulates expression of 
hepatic transcription factors SREBP1 
and PPARα and hepatic enzymes 
and transporters involved in fatty acid 
synthesis, metabolism, and transport. 
mRNA expression of genes in hepatic 
tissue was assessed by real-time PCR 
and normalized to GAPDH. (A) mRNA 
expression of CD73 and adenosine 
receptors (%, versus control). (B) mRNA 
expression of Srebp1. (C) mRNA expres-
sion of Ppara. (D) mRNA expression of 
Pparg. (E) mRNA expression of Acl. (F) 
mRNA expression of Fas. (G) mRNA 
expression of Acca. (H) mRNA expres-
sion of Cpt1. *P < 0.01, ethanol versus 
control in different groups, respectively; 
**P < 0.01, DPCPX or enprofylline-
treated mice versus ethanol WT mice, 
respectively; n = 5 in each group.
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not previously been explored, the demonstration that adenosine 
and its receptors mediate ethanol-induced changes in hepatic 
function is not without precedent.
Previous studies provide indirect support for a role for adenosine 
and its receptors in the pathogenesis of fatty liver. Muroyama et al. 
(41) found that ingestion of a mixture of caffeine, arginine, thiamine, 
and citric acid reduced body fat, triceps skinfold thickness, and serum 
triglyceride levels in healthy human subjects with a high percentage 
of body fat and was effective in reducing visceral fat, including liver 
fat, in obese subjects. Caffeine, a nonselective adenosine receptor 
antagonist, in combination with vitamins and arginine, significantly 
suppressed an increase in hepatic lipid content in fasted and refed 
diabetic KK mice (42, 43). Thus, adenosine receptors may also play a 
role in the pathogenesis of nonalcoholic fatty liver as well.
Figure 5
Adenosine A1 and A2B agonists promote fat accumulation in a cultured murine hepatocyte cell line (AML-12 cells). Cells were treated with adenos-
ine receptor agonists or antagonists or their combination (A1 receptor agonist CPA, 1 μM; DPCPX, 1 μM; A2A receptor antagonist ZM 241385 
[ZM], 1 μM; nonselective and A2B receptor agonist NECA, 10 μM; A2B receptor antagonist MRS1706, 1 μM; A3 receptor antagonist 3-ethyl-5-ben-
zyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-( ± )-diphydropyridine-3,5-dicarboxylate [MRS1191], 1 μM) for 24 hours, then stained with Oil Red O, 
or collected and the cellular triglyceride content was measured. (A) Oil red O staining of AML-12 hepatocytic cells (original magnification, ×400). 
(B) Curve of cellular triglyceride content of AML-12 cells with CPA concentration. (C) Curve of cellular triglyceride content of AML-12 cells with 
NECA concentration. (D) Cellular triglyceride content of AML-12 cells after CPA or antagonists or CPA combined with antagonist treatment. (E) 
Cellular triglyceride content of AML-12 cells after NECA or NECA combined with antagonist treatment. The data are expressed as percentages 
of control (mean ± SD) from 4 independent experiments. *P < 0.01, CPA or CPA plus ZM, MRS1706, or MRS1191 or NECA or NECA plus ZM 
or MRS1191 versus control, respectively; **P < 0.01, CPA plus DPCPX versus CPA; #P < 0.01, NECA plus DPCPX versus control or NECA, 
respectively; ##P < 0.01, NECA plus MRS1706 versus NECA or NECA plus DPCPX, respectively.
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Recently, Osei-Hyiaman et al. (44) found that endocannabinoid 
activation of hepatic cannabinoid receptors (CB1 receptors) is asso-
ciated with development of diet-induced hepatic steatosis in mice, 
and others have reported that ethanol ingestion leads to stellate 
cell production of endocannabinoids, which activate hepatic CB1 
receptors on hepatocytes, leading to hepatic steatosis (45). Treat-
ment of rats with cannabinoid receptor antagonists prevents the 
development of fatty liver in animal models as well (46, 47). In 
the CNS, adenosine A1 receptors are tightly linked to CB1 recep-
tors and these receptors cross-activate and cross-desensitize each 
other (48–51), although their interaction in the liver has not been 
explored. The results reported here are consistent with and expand 
upon the known link between cannabinoid receptors and adenos-
ine receptors and further suggest that adenosine receptors play a 
role in nonalcoholic hepatic steatosis.
Prior studies, as well as the results reported here, clearly demon-
strate that adenosine A1, A2A, A2B, and A3 receptors are expressed 
on hepatocytes (11–14, 52, 53) and chronic ethanol ingestion 
increases A1, A2A, and A2B receptor expression in the liver. Adenos-
ine receptors are expressed ubiquitously and other cell types in 
the liver express adenosine receptors as well: stellate cells express 
adenosine A1, A2A, and A2B receptors (4, 5, 54); Kupffer cells and 
sinusoidal endothelial cells express adenosine A2A receptors (55). 
Since ethanol has a variety of CNS effects, many of which are due 
to increased CNS adenosine levels with resulting A2A receptor acti-
vation (56, 57), it is also possible that extrahepatic effects of ade-
nosine may lead to hepatic steatosis by, for example, production 
of neuroendocrine mediators or increased food intake. However, 
the demonstration that adenosine A1 and A2B receptors directly 
stimulate steatosis in AML-12 hepatocytic cells is more consistent 
with the hypothesis that adenosine receptors directly regulate 
hepatocyte metabolism.
Alterations in 3 major regulatory pathways in the hepatocyte con-
tribute to the development of fatty liver: stimulation of SREBP1 
activation, inhibition of AMPK, and diminished PPARα activa-
tion/increased PPARγ activation. SREBP1 is a member of the basic 
helix-loop-helix leucine zipper (bHLH-ZIP) family of transcrip-
tion factors that is synthesized as a 125-kDa precursor attached 
to the nuclear envelope and endoplasmic reticulum (58, 59). In 
sterol-depleted cells, the membrane-bound precursor is cleaved 
to generate a soluble NH2-terminal fragment that translocates 
to the nucleus (60). SREBP1 plays an active role in regulating 
the transcription of genes involved in hepatic triglyceride syn-
thesis (including ACC, FAS, stearoyl-CoA desaturase-1, ACL, and 
l-α-glycerophosphate acyltransferase; refs. 61, 62). Ethanol and its 
metabolites activate SREBP1 (63), and alcohol-induced fatty liver 
Figure 6
Adenosine A1 and A2B recep-
tors regulate nuclear SREBP1, 
PPARα, and PPARγ protein 
levels and transcriptional activ-
ity in AML-12 cells. AML-12 
hepatocytes were treated with 
the adenosine receptor agonists 
or antagonists or their combina-
tion (CPA, 1 μM; DPCPX, 1 μM; 
NECA, 10 μM; MRS1706, 1 μM) 
followed by isolation of nuclei 
protein. SREBP1, PPARα, 
and PPARγ protein levels were 
assessed by Western blotting 
and normalized to nuclear pro-
tein P-84, and densitometry 
was used to quantitate protein 
expression. (A) Western blot of 
nuclear SREBP1, PPARα, and 
PPARγ. (B) Nuclear SREBP1 
protein levels after 12 hours 
of treatment. (C) Nuclear 
PPARα protein levels after 1 
hour of treatment. (D) Nuclear 
PPARγ protein levels after 1 
hour of treatment. (E) PPARα 
transcriptional activity after 1 
hour of treatment. (F) PPARγ 
transcriptional activity after 1 
hour of treatment. The data 
are expressed as percentages 
of control (mean ± SD) from 
4 independent experiments. 
*P < 0.01, versus control or other 
treatment groups, respectively.
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correlates with activation and induction of SREBP1 (30, 63, 64). In 
our studies ethanol and adenosine A1 receptor occupancy signifi-
cantly increased nuclear SREBP1 and downstream expression of 
ACL and FAS mRNA expression, both deletion and antagonism of 
adenosine A1 receptors significantly diminished their expression 
in vivo and in vitro (Figures 4 and 7). These results are consistent 
with the hypothesis that adenosine A1 receptors regulate SREBP1 
expression and activation to increase expression of fatty acid syn-
thetic enzymes (Figure 9).
PPARα, -β/δ, and -γ belong to the nuclear receptor superfamily 
(65). PPARα is activated by sterols and is translocated to the nucle-
us, in which it stimulates the transcription of a variety of enzymes 
and transporters that promote fatty acid oxidation (23–25). Ethanol 
prevents the activation and nuclear translocation of PPARα (66–69), 
effects abrogated by deletion or blockade of adenosine A2B receptors. 
In contrast to PPARα, PPARγ appears to play a direct role in the 
development of fatty liver (46, 70–73). PPARγ is expressed at very 
low levels in the liver, and overexpression in the liver leads to hepatic 
steatosis with the expression of several adipogenic genes (26–29). 
Conversely, PPARγ agonists have been used to treat nonalcoholic 
fatty liver (74), possibly by increasing expression of the receptor 
for adiponectin (75). Ethanol increases Pparg mRNA expression 
and expression of lipid synthetic enzymes ACL and FAS in mouse 
liver, and deletion or blockade of adenosine A1 receptors decreased 
expression of these genes consistent with the results of the in vitro 
hepatocyte experiments. These results suggest the hypothesis that 
adenosine A1 and A2B receptors regulate PPARγ and PPARα activa-
tion and expression to promote hepatic steatosis (Figure 9).
AMPK also plays a key role in the regulation of cellular metabo-
lism. Once activated by phosphorylation of threonine-172 or by 
AMP, AMPK strongly activates ACC, 3-hydroxy-3-methyl-gluta-
ryl-CoA reductase, and other targets, leading to fatty acid oxida-
tion and diminished cholesterol synthesis (31, 76–78). Ethanol 
inhibits AMPK activation, leading to accumulation of fatty acids 
within the hepatocyte (30). Alcohol ingestion diminished AMPK 
phosphorylation in mouse liver, an effect reversed by deletion or 
blockade of adenosine A2B receptors but not A1 receptors. Studies 
carried out in vitro provided parallel results. Thus, adenosine A2B 
receptors are also likely to promote hepatic triglyceride accumula-
tion by diminishing AMPK phosphorylation and activity as well as 
by diminishing PPARα transcriptional activity (Figure 9).
We demonstrated, for the first time to our knowledge, that all 
4 adenosine receptors are present in healthy human liver plasma 
membranes. The number and affinity of adenosine A1 and A3 recep-
tors does not change in cirrhotic and fatty livers but the number of 
A2A and A2B receptors increases in cirrhotic and fatty livers. Prior 
studies have demonstrated a number of factors that may regulate 
the expression of adenosine A2A receptors, including such inflam-
Figure 7
Adenosine A1 and A2B receptors regu-
late enzymes involved in fatty acid 
synthesis and oxidation. AML-12 
hepatocytes were treated with adenos-
ine receptor agonists or antagonists or 
their combination (CPA, 1 μM; DPCPX, 
1 μM; NECA, 10 μM; MRS1706, 1 μM) 
for 24 hours, cells were lysed, and 
the protein levels were assessed 
by Western blotting, quantitated by 
densitometry, and normalized to β-actin. 
(A) Representative Western blot of 
ACL, FAS, ACCα, and CPTI. (B) ACL 
protein levels. (C) FAS protein levels. 
(D) ACCα protein levels. (E) CPTI pro-
tein levels. The data are expressed as 
percentage of control (mean ± SD) from 
at least 3 independent experiments. 
*P < 0.01, versus control or other treat-
ment groups, respectively.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 3   March 2009 591
matory cytokines as IL-1 and TNF (79, 80) and endotoxin (81). 
Interferon-γ, which stimulates increased expression of A2B receptors 
(82), may diminish A2A and A2B receptor signaling (79, 80, 83).
The results reported here demonstrate what we believe to be a 
novel pathogenic mechanism for the development of fatty liver 
following chronic ethanol ingestion: ethanol-induced adenosine 
release stimulates hepatic steatosis via activation of A1 and A2B 
receptors. It is also possible that adenosine and its receptors play a 
role in the pathogenesis of nonalcoholic fatty liver disease as well. 
Moreover, these results suggest that adenosine receptor antago-
nism may provide a novel approach for the development of agents 
for the treatment and prevention of alcoholic and, possibly, non-
alcoholic fatty liver disease.
Methods
Reagents. A1 receptor agonist CPA (84), A1 receptor antagonist DPCPX (84), 
nonselective adenosine receptor agonist NECA (84), A2B antagonist 3-pro-
pylxanthine (enprofylline) (85, 86), and A3 antagonist, 3-ethyl-5-benzyl-2-
methyl-4-phenylethynyl-6-phenyl-1,4-( ± )-diphydropyridine-3,5-dicarbox-
ylate (MRS1191) (84) were obtained from Sigma-Aldrich. A more potent and 
selective A2B receptor antagonist MRS1706 
(84) and A2A antagonist 4-(2-[7-amino-2-
(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-
5-ylamino]ethyl)phenol (ZM 241385) (84) 
were purchased from Tocris Cookson. [3H]-
DPCPX (specific activity, 120 Ci/mmol) was 
obtained from Perkin Elmer Life and Ana-
lytical Sciences. [3H]-ZM 241385 (specific 
activity, 17 Ci/mmol) was obtained from 
Tocris Cookson Ltd. N-benzo[1,3]dioxol-5-
yl-2-[5-(1,3-dipropyl-2,6-dioxo-2,3,6,7-tetra-
hydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-
3-yloxy]-acetamide] ([3H]-MRE 2029F20, 
A2B receptor antagonist; specific activity, 
123 Ci/mmol) and 5-N-(4-methoxyphenyl-
carbamoyl)amino-8-propyl-2(2furyl)-pyr-
azolo-[4,3e]-1,2,4-triazolo [1,5-c] pyrimi-
dine ([3H]-MRE 3008F20, A3 receptor 
antagonist; specific activity, 67 Ci/mmol) 
were derived from Amersham International 
Chemical Laboratories.
Animals. C57BL/6 WT mice were pur-
chased from The Jackson Laboratory. 
CD73KO mice were provided as a gift by 
Linda Thompson (Oklahoma Medical 
Research Foundation, Oklahoma City, 
Oklahoma, USA) (87). A1KO mice were a 
gift of Bertil Fredholm (Karolinska Insti-
tutet, Stockholm, Sweden) (88). CD73 
and A1 receptor knockout mice were bred 
onto a C57BL/6 background (>10 back-
crosses) in the New York University School 
of Medicine Animal Facility. A2BKO mice 
(C57BL/6 background) have been previous-
ly described (89). A2AKO mice (S129 mixed 
background) and their corresponding WT 
littermates (90) were bred in the New York 
University School of Medicine Animal Facil-
ity. All experimental mice were 6- to 8-week-
old male mice. All experimental procedures 
were approved by and performed in accordance with the guidelines of the 
Institutional Animal Care and Use Committee of the School of Medicine 
of New York University.
Mouse model of fatty liver and treatment. Mice were fed an ethanol-contain-
ing liquid Lieber-DeCarli (BioServ Inc.) diet or a calorie equivalent Lieber-
DeCarli diet supplemented with maltose (BioServ Inc.) for 6 weeks. This 
diet provides 35.5% of calories from ethanol (or maltose), 35% of calories 
from fat, 18% of calories from protein, and 11.5% of calories from car-
bohydrate. For the first 2 weeks, animals were gradually introduced to 
the ethanol-containing liquid diet, including liquid diet acclimation for 
4 days, 0.75% ethanol (w/v) for 3 days, 1.50% ethanol (w/v) for 3 days, 3.75% 
ethanol (w/v) for 4 days, and then 5.00% ethanol (w/v) diet for 4 weeks (91, 
92). Animal cages were placed on heating pads to maintain body tempera-
ture. Mice were weighed before and after experiments, and measurements 
of daily food consumption were recorded. A1 receptor antagonist DPCPX 
(50 mg/kg/d) or A2B receptor antagonist enprofylline (50 mg/kg/d) were 
administered to WT mice in the liquid diet, and all animals had free access 
to the liquid diet throughout the experimental period. There was no sig-
nificant difference in food intake among the different groups of mice (data 
not shown) and weight gain was similar for all of the mice studied (Table 1), 
Figure 8
Adenosine A2B receptors regulate the phosphorylation of AMPK, a critical signaling molecule con-
trolling the pathways of hepatic fatty acid oxidation Liver tissues from control- or ethanol-treated 
WT and KO mice or WT mice treated with adenosine A1 or A2B receptor antagonists were col-
lected and the protein was isolated as described in Methods. AML-12 hepatocytes were treated 
with adenosine receptor agonists or antagonists or their combination (CPA, 1 μM; DPCPX, 1 μM; 
NECA, 10 μM; MRS1706, 1 μM) for 10 minutes, cells were lysed and the protein was isolated. 
AMPK, phosphorylated AMPK (PAMPK) levels in hepatic tissues, and cultured hepatocytes were 
assessed by Western blotting and quantitated by densitometry, and the PAMPK/AMPK/β-actin pro-
tein ratio was calculated. (A) Western blotting of PAMPK, AMPK, and β-actin in hepatic tissue. (B) 
PAMPK/AMPK/β-actin protein ratio in hepatic tissue (n = 5 in each group). (C) Western blotting 
of PAMPK, AMPK, and β-actin in cultured hepatocytes. (D) PAMPK/AMPK/β-actin protein ratio in 
cultured hepatocytes. The data are expressed as percentages of control (mean ± SD) from at least 
3 in vitro independent experiments. *P < 0.05, ethanol-treated versus control; **P < 0.05, enprofyl-
line-treated mice versus WT mice with vehicle or ethanol, respectively; #P < 0.01, versus control or 
other treatment groups, respectively.
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except for animals that developed fatty liver (WT and A2AKO mice fed 
ethanol), which did not gain as much weight as the mice fed the maltose-
containing diet (Table 1). Mice were sacrificed by CO2 narcosis at the end 
of the experiment, and their blood and livers were collected. Two WT mice 
(2/22) and one CD73KO mouse (1/10) died during the introduction phase, 
prior to administration of the full dose of ethanol. No other mice died dur-
ing the course of these experiments.
H&E and Oil Red O staining of liver sections. Livers were fixed with 10% neu-
tral formalin, embedded in paraffin, and stained with H&E for histological 
examination. Liver steatosis was graded as previously described (93), based 
on semiquantitative estimation of the percentage of lipid-laden hepatocytes, 
according to the following criteria: grade 0, no hepatocytes involved; grade 1, 
1%–25% of hepatocytes involved; grade 2, 26%–50% of hepatocytes involved; 
grade 3, 51%–75% of hepatocytes involved; and grade 4, 76%–100% of 
hepatocytes involved. At least 5 different high-power fields (original magni-
fication, ×400) were graded in a blinded way. For Oil Red O (Sigma-Aldrich) 
staining, liver sections were flash-frozen and embedded in frozen medium 
(Optimal Cutting Temperature Compound, Ted Pella). The 5-μm sections 
were cut and fixed to microscope slides, allowed to air dry overnight at room 
temperature and stained with fresh Oil Red O for 15 minutes, rinsed in 
water, and then counterstained with hematoxylin.
Measurements of serum alanine aminotransferase, AST, and triglycerides. Whole 
blood was taken from mice at the time of sacrifice and serum was isolated. 
Alanine aminotransferase, AST, and triglycerides were measured by standard 
techniques in the Clinical Laboratory of Bel-
levue Hospital, New York, New York, USA.
Hepatic triglyceride measurement. Hepatic 
triglyceride measurements were made as 
previously described (93). In brief, liver tis-
sue was homogenized at 4°C in RIPA lysis 
buffer (Sigma-Aldrich). Lipids from total 
liver homogenate were extracted using 
chloroform/methanol method (2:1), evap-
orated, and dissolved in 2-propanol. Tri-
glyceride concentration was assayed using 
kits obtained from Sigma-Aldrich follow-
ing the manufacturers’ instructions.
Hepatocyte cell culture, triglyceride measure-
ment, and Oil Red O staining of hepatocytes. 
The mouse hepatocyte cell line AML-12 was obtained from ATCC. These 
cells exhibit a differentiated and nontransformed hepatocyte phenotype 
and have been previously used in numerous studies of hepatocyte injury 
(29). AML-12 cells were grown in a 1:1 mixture of DMEM-Ham’s F-12 
medium (Invitrogen) supplemented with 0.005 mg/ml insulin, 0.005 
mg/ml transferrin, 5 ng/ml selenium, 40 ng/ml dexamethasone, 10% fetal 
bovine serum, and antibiotics. Upon reaching 70%–80% confluence, cells 
were treated for 6 hours in serum-free DMEM-Ham’s F-12 medium and 
then were treated with different adenosine receptor agonists, antagonists, 
or vehicle (DMSO, 1.28 × 10–5M), respectively. Triglyceride content and Oil 
Red O staining was carried out as described above.
Real-time PCR quantitation of mRNA. Total RNA was isolated from liver 
tissue using TRIzOl reagent (Invitrogen), and RNA was extracted accord-
ing to the manufacturer’s instructions, then dissolved in sterile diethyl 
pyrocarbonate (DEPC; Sigma-Aldrich) water, and stored at –80°C. One 
microgram of sample RNA was transcribed to cDNA with the GeneAmp 
RNA Core Kit (Applied Biosystems Inc.). Primer sequences used are listed 
in Supplemental Table 1. PCR was performed with the SYBR Green PCR 
Kit (Applied Biosystems Inc.) following the manufacturer’s instructions 
and carried out on the Mx3005P Q-PCR System (Stratagene) in 50-μl vol-
ume. The number of copies for each amplicon was calculated by Mx3005P 
software, normalized to GAPDH, and expressed as a dimensionless ratio.
Western blotting and complete transcription factor measurement. Cells were 
lysed with RIPA buffer (Sigma-Aldrich), and tissue protein extraction was 
with T-PER Tissue Protein Extraction Reagent (Pierce) after tissue was 
homogenized. The nuclear protein extractions were completed with NE-
PER Nuclear and Cytoplasmic Extraction Reagents (Pierce), per the manu-
facturer’s instructions. The extracted nuclear protein was used for Western 
blot or transcription factor assay. ACL, FAS, and phospho-AMPKα antibod-
ies were purchased from Cell Signaling Technology; AMPKα, ACCα, and 
CPTI antibodies were from Santa Cruz Biotechnology Inc.; and SREBP1, 
PPARα, PPARγ, β-actin, and nuclear matrix protein p84 (P84) antibodies 
were from ABCAM. Proteins were separated by electrophoresis through 
10% SDS-polyacrylamide gels and then transferred to nitrocellulose mem-
branes. Western blot analyses were performed as previously described (79). 
The PPARα, PPARγ transcription factor assay was carried out by ELISA 
following the manufacturer’s instructions (Cayman Chemical).
Preparation of human liver membranes. Fresh de-identified specimens of 
liver were obtained from liver tissue not used for transplant or after remov-
al for liver transplant and maintained in a frozen tissue bank at Ferrara 
University by the Department of Surgery, Anesthesiology, and Radiology 
and Department of Biomedical Sciences and Advanced Therapy. The nor-
mal control liver specimens were matched for age of patients. Each sample 
was immediately frozen in liquid nitrogen and stored at –80°C until the 
assays were performed. The liver tissues were homogenized and filtered 
Table 2
Binding parameters of adenosine receptors in different human hepatic substrates
Human	hepatic		 	 Adenosine	receptors
membranes	 	 A1	 A2A	 A2B	 A3
Control subjects (n = 10) Kd 2.11 ± 0.17 1.67 ± 0.15 2.19 ± 0.16 4.53 ± 0.27
 Bmax 33 ± 3 74 ± 5 68 ± 4 526 ± 25
Cirrhotic patients (n = 3) Kd 2.02 ± 0.19 3.42 ± 0.22A 3.28 ± 0.24A 4.95 ± 0.28
 Bmax 31 ± 3 240 ± 21A 125 ± 8A 543 ± 23
Steatotic patients (n = 10) Kd 1.95 ± 0.15 4.09 ± 0.27A 3.85 ± 0.29A 4.36 ± 0.21
 Bmax 34 ± 3 363 ± 23A 157 ± 10A 494 ± 28
Bmax, maximal binding, is measured in fmol/mg protein; Kd is measured in nM. AP < 0.01, versus control 
subjects.
Figure 9
Ethanol-induced adenosine release provokes fatty change via adenos-
ine A1 and A2B receptor–mediated stimulation of increased fatty acid 
synthesis and diminished fatty acid utilization, respectively.
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through 2 layers of gauze, and the homogenate was centrifuged at 100,000 g 
for 30 minutes, followed by resuspension of the pellet in a buffer contain-
ing 2 IU/ml of adenosine deaminase and incubation for 30 minutes at 
37°C. The suspension was centrifuged again and the final pellet was used 
for radioligand binding assays. Collection of human tissues was approved 
by the Ethical Committee of the Provincia di Ferrara, Italy. Informed con-
sent for use of tissue in these experiments was not obtained as the tissue 
was provided without identifiers.
[3H]-DPCPX, [3H]-ZM 241385, [3H]-MRE 2029F20, and [3H]-MRE3008F20 
binding assays to human A1, A2A, A2B, and A3 adenosine receptors, respectively. Sat-
uration binding experiments were performed as previously described using 
[3H]-DPCPX, [3H]-ZM 241385, [3H]-MRE 2029F20, and [3H]-MRE3008F20 
as radioligands (94–97). The membranes (60–100 μg of protein/assay) 
obtained from human healthy or diseased liver tissues were incubated with 
8 to 10 concentrations of the radioligand [3H]-DPCPX, [3H]-ZM 241385, 
[3H]-MRE 2029F20, and [3H]-MRE3008F20 (0.01–40 nM) for 60–150 min-
utes at 4°C–25°C. Nonspecific binding was determined in the presence of 
excess unlabelled DPCPX, ZM 241385, MRE 2029F20, and MRE3008F20 
(1 μM). Bound and free radioactivity was separated by filtering the assay 
mixture through Whatman GF/B glass fiber filters using a Brandel cell 
harvester. The filter bound radioactivity was counted using a Packard 2500 
TR Liquid Scintillation Counter with an efficiency of 58%. The protein 
concentration was determined by Bio-Rad protein assay (98) with bovine 
albumin as reference standard.
Statistics. Data were expressed as mean ± SD and were analyzed by 
Student’s t test or ANOVA analysis, as appropriate, with SPSS software 
(SigmaStat) 10.0. P values of less than 0.05 were considered to be statisti-
cally significant.
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